US5629178A
(en)
*
|
1994-10-28 |
1997-05-13 |
Genetics & Ivf Institute |
Method for enhancing amplification in the polymerase chain reaction employing peptide nucleic acid (PNA)
|
AU693023B2
(en)
*
|
1995-05-05 |
1998-06-18 |
Applied Biosystems, Llc |
Methods and reagents for combined PCR amplification and hybridization probing assay
|
US5939262A
(en)
|
1996-07-03 |
1999-08-17 |
Ambion, Inc. |
Ribonuclease resistant RNA preparation and utilization
|
US5677124A
(en)
*
|
1996-07-03 |
1997-10-14 |
Ambion, Inc. |
Ribonuclease resistant viral RNA standards
|
US6617422B1
(en)
|
1997-05-23 |
2003-09-09 |
Peter Nielsen |
Peptide nucleic acid monomers and oligomers
|
US6485901B1
(en)
|
1997-10-27 |
2002-11-26 |
Boston Probes, Inc. |
Methods, kits and compositions pertaining to linear beacons
|
DE60045350D1
(de)
|
1999-06-01 |
2011-01-20 |
Baylor College Medicine |
Zusammensetzungen und verfahren zur therapeutischen anwendung einer mit dem gen atonal assoziierten sequenz
|
AU2001229576A1
(en)
*
|
2000-01-15 |
2001-07-24 |
Genelabs Technologies, Inc. |
Nucleic acid binding site assay and selection method
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
US20030166282A1
(en)
|
2002-02-01 |
2003-09-04 |
David Brown |
High potency siRNAS for reducing the expression of target genes
|
EP2221377B2
(en)
|
2002-02-01 |
2017-05-17 |
Life Technologies Corporation |
Oligonucleotide compositions with enhanced efficiency
|
US20030211483A1
(en)
*
|
2002-05-09 |
2003-11-13 |
Schroeder Benjamin G. |
Methods for the enrichment of low-abundance polynucleotides
|
EP2269619A1
(en)
|
2002-08-12 |
2011-01-05 |
Jennerex Biotherapeutics ULC |
Methods and compositions concerning poxviruses and cancer
|
CA2581086C
(en)
|
2004-09-14 |
2023-11-07 |
The Regents Of The University Of Colorado, A Body Corporate |
Method for treatment with bucindolol based on genetic targeting
|
EP2333561A3
(en)
|
2005-03-10 |
2014-06-11 |
Gen-Probe Incorporated |
System for performing multi-formatted assays
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
CA2621982C
(en)
*
|
2005-09-07 |
2017-11-28 |
Jennerex Biotherapeutics Ulc |
Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
|
DE602007006478D1
(de)
|
2006-05-12 |
2010-06-24 |
Cepheid Sunnyvale |
Erkennung der verbindung einer dna-rekombination
|
CN102026645B
(zh)
|
2006-09-15 |
2016-01-27 |
渥太华医院研究机构 |
溶瘤弹状病毒
|
US20100129902A1
(en)
*
|
2008-11-24 |
2010-05-27 |
Erhard Ralf Schoenbrunner |
Replication Stable and RNase Resistant Chimeras of Pestivirus with Insertion in 3' Nontranslated Region (3'NTR)
|
US9587270B2
(en)
|
2009-06-29 |
2017-03-07 |
Luminex Corporation |
Chimeric primers with hairpin conformations and methods of using same
|
US9409983B2
(en)
|
2009-07-23 |
2016-08-09 |
The Board Of Trustess Of The University Of Illinois |
Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
|
WO2011032088A1
(en)
|
2009-09-11 |
2011-03-17 |
Arca Biopharma, Inc. |
Polymorphisms in the pde3a gene
|
ES2848650T3
(es)
|
2009-09-14 |
2021-08-11 |
Sillajen Biotherapeutics Inc |
Terapia combinada contra el cáncer con virus vaccinia oncolítico
|
AU2010329551B2
(en)
|
2009-12-10 |
2016-02-11 |
Turnstone Limited Partnership |
Oncolytic rhabdovirus
|
DK2515899T3
(da)
|
2009-12-23 |
2016-08-15 |
Arca Biopharma Inc |
Fremgangsmåder og sammensætninger til kardiovaskulære sygdomme og tilstande
|
CN103429258B
(zh)
|
2011-01-04 |
2016-03-09 |
新罗杰公司 |
通过施用溶瘤痘苗病毒生成针对肿瘤抗原的抗体和生成肿瘤特异性补体依赖性细胞毒性
|
CA2828532A1
(en)
|
2011-02-28 |
2012-11-22 |
University Of Iowa Research Foundation |
Anti-mullerian hormone changes in pregnancy and prediction of adverse pregnancy outcomes and gender
|
AU2012226530B2
(en)
|
2011-03-08 |
2016-12-01 |
King Abdullah University Of Science And Technology |
Molecular biomarker set for early detection of ovarian cancer
|
WO2012167382A1
(en)
|
2011-06-08 |
2012-12-13 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Compositions and methods for glioblastoma treatment
|
US10040853B2
(en)
|
2011-09-09 |
2018-08-07 |
Fred Hutchinson Cancer Research Center |
Methods and compositions involving NKG2D inhibitors and cancer
|
US10125373B2
(en)
|
2013-01-22 |
2018-11-13 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Geminiviral vector for expression of rituximab
|
RU2684211C2
(ru)
|
2013-02-21 |
2019-04-04 |
Тёрнстоун Лимитед Партнершип |
Композиция вакцины
|
WO2015051110A1
(en)
|
2013-10-03 |
2015-04-09 |
Oklahoma Medical Research Foundation |
Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare
|
WO2015104684A1
(en)
|
2014-01-10 |
2015-07-16 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Hydroxy formamide derivatives and their use
|
GB201411567D0
(en)
*
|
2014-06-30 |
2014-08-13 |
Epistem Ltd |
Quantification methods
|
EP3224362A4
(en)
|
2014-11-26 |
2018-06-06 |
The Regents of The University of California |
Therapeutic compositions comprising transcription factors and methods of making and using the same
|
US20190390278A1
(en)
|
2017-01-26 |
2019-12-26 |
Oklahoma Medical Research Foundation |
Biomarkers for systemic lupus erythematosus disease activity, and intensity and flare
|
KR102554477B1
(ko)
|
2018-10-18 |
2023-07-11 |
오클라호마 메디컬 리써치 화운데이션 |
질병 활성도의 특징을 규명하는 전신 홍반성 낭창(sle) 질병 활성도 면역 지수를 위한 생체지표
|
AU2019371161A1
(en)
|
2018-10-31 |
2021-06-17 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Biomarkers and methods of use for radiation-induced lung injury
|